Vorinostat Completed Phase 1 Trials for Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Secondary Myelodysplastic Syndromes / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Recurrent Adult Acute Myeloid Leukemia / Adult Acute Basophilic Leukemia / Adult Acute Monoblastic Leukemia (M5a) / Essential Thrombocythemia (ET) / Adult Erythroleukemia (M6a) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Myelomonocytic Leukemia (M4) / Accelerated Phase Chronic Myelogenous Leukemia / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Pure Erythroid Leukemia (M6b) / Relapsing Chronic Myelogenous Leukemia / Adult Acute Promyelocytic Leukemia (M3) / Recurrent Adult Acute Lymphoblastic Leukemia / Chronic Neutrophilic Leukemia / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / De Novo Myelodysplastic Syndromes / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Previously Treated Myelodysplastic Syndromes / Primary Myelofibrosis / Polycythemia Vera (PV) / Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Eosinophilic Leukemia / Adult Acute Monocytic Leukemia (M5b) / Chronic Myelomonocytic Leukemia / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Blastic Phase Chronic Myelogenous Leukemia / Chronic Eosinophilic Leukemia (CEL) / Secondary Acute Myeloid Leukemia (Secondary AML, sAML) Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00357305Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders